# Olaf van Tellingen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2891912/publications.pdf

Version: 2024-02-01

| 181 | 13,035 | 26630 56 | 24258 110 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 184 | 184 | 184 | 14984 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell, 1994, 77, 491-502. | 28.9 | 2,163 |
| 2 | Overcoming the bloodâ€“brain tumor barrier for effective glioblastoma treatment. Drug Resistance Updates, 2015, 19, 1-12. | 14.4 | 706 |
| 3 | Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Molecular Cancer Therapeutics, 2002, 1, 417-25. | 4.1 | 371 |
| 4 | The Effect of Bcrp1 (Abcg2) on the In vivo Pharmacokinetics and Brain Penetration of Imatinib Mesylate (Gleevec): Implications for the Use of Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors to Enable the Brain Penetration of Imatinib in Patients. Cancer Research, 2005, 65, 2577-2582. | 0.9 | 338 |
| 5 | Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. Journal of Clinical Investigation, 1999, 104, 1441-1447. | 8.2 | 314 |
| 6 | Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nature Communications, 2013, 4, 1908. | 12.8 | 310 |
| 7 | Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12117-12122. | 7.1 | 279 |
| 8 | Bmi1 Controls Tumor Development in an Ink4a/Arf-Independent Manner in a Mouse Model for Glioma. Cancer Cell, 2007, 12, 328-341. | 16.8 | 264 |
| 9 | P-Glycoprotein and Breast Cancer Resistance Protein: Two Dominant Transporters Working Together in Limiting the Brain Penetration of Topotecan. Clinical Cancer Research, 2007, 13, 6440-6449. | 7.0 | 252 |
| 10 | Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles. Cancer Research, 2004, 64, 5804-5811. | 0.9 | 222 |
| 11 | Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. Journal of Clinical Investigation, 2007, 117, 3583-3592. | 8.2 | 210 |
| 12 | Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat. Behavioural Brain Research, 2008, 186, 168-175. | 2.2 | 209 |
| 13 | Pharmacokinetics, Brain Delivery, and Efficacy in Brain Tumor-Bearing Mice of Glutathione Pegylated Liposomal Doxorubicin (2B3-101). PLoS ONE, 2014, 9, e82331. | 2.5 | 207 |
| 14 | Tumour-specific proline vulnerability uncovered by differential ribosome codon reading. Nature, 2016, 530, 490-494. | 27.8 | 202 |
| 15 | MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. International Journal of Cancer, 2005, 116, 824-829. | 5.1 | 189 |
| 16 | Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition inin vitroandin vivopharmacokinetic studies employing Bcrp1â^'/â^'/Mdr1a/1bâ^'/â^' (triple-knockout) and wild-type mice. Molecular Cancer Therapeutics, 2008, 7, 2280-2287. | 4.1 | 183 |
| 17 | Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein. Clinical Cancer Research, 2003, 9, 2849-55. | 7.0 | 183 |
| 18 | Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 7257-7262. | 7.1 | 182 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Modulation of the bloodâ€“brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours?. Cancer Treatment Reviews, 2004, 30, 415-423. | 7.7 | 174 |
| 20 | Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer, 2009, 9, 444. | 2.6 | 166 |
| 21 | Carcinogen and Anticancer Drug Transport by Mrp2 in Vivo: Studies UsingMrp2(Abcc2) Knockout Mice. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 319-327. | 2.5 | 146 |
| 22 | Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. Investigational New Drugs, 2012, 30, 443-449. | 2.6 | 135 |
| 23 | The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Investigational New Drugs, 2009, 27, 31-40. | 2.6 | 132 |
| 24 | Preclinical pharmacokinetics of paclitaxel and docetaxel. Anti-Cancer Drugs, 1998, 9, 1-17. | 1.4 | 125 |
| 25 | Modulation of oral bioavailability of anticancer drugs: from mouse to man. European Journal of Pharmaceutical Sciences, 2000, 12, 103-110. | 4.0 | 125 |
| 26 | Bloodâ€“brain barrier and chemotherapeutic treatment of brain tumors. Expert Review of Neurotherapeutics, 2006, 6, 1199-1209. | 2.8 | 124 |
| 27 | Validity of bioluminescence measurements for noninvasive in vivo imaging of tumor load in small animals. BioTechniques, 2007, 43, S7-S13, S30. | 1.8 | 121 |
| 28 | The Functional Role of P-Glycoprotein in the Bloodâ€“Brain Barrier. Journal of Pharmaceutical Sciences, 1997, 86, 881-884. | 3.3 | 119 |
| 29 | Chemotherapy-related cognitive dysfunction: current animal studies and future directions. Brain Imaging and Behavior, 2013, 7, 453-459. | 2.1 | 118 |
| 30 | Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Research, 2002, 62, 6158-64. | 0.9 | 116 |
| 31 | Tissue distribution, metabolism and excretion of paclitaxel in mice. Anti-Cancer Drugs, 1996, 7, 78-86. | 1.4 | 106 |
| 32 | ABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy. Clinical Cancer Research, 2014, 20, 2703-2713. | 7.0 | 105 |
| 33 | A Phase I Study of the P-Glycoprotein Antagonist Tariquidar in Combination with Vinorelbine. Clinical Cancer Research, 2009, 15, 3574-3582. | 7.0 | 101 |
| 34 | Effects of the Selective MPS1 Inhibitor MPS1-IN-3 on Glioblastoma Sensitivity to Antimitotic Drugs. Journal of the National Cancer Institute, 2013, 105, 1322-1331. | 6.3 | 94 |
| 35 | Uncoupling DNA damage from chromatin damage to detoxify doxorubicin. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 15182-15192. | 7.1 | 93 |
| 36 | Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Research, 2003, 63, 1339-44. | 0.9 | 89 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Multidrug Resistance Protein 2 Is an Important Determinant of Paclitaxel Pharmacokinetics. Clinical Cancer Research, 2006, 12, 6125-6132. | 7.0 | 88 |
| 38 | Absence of Both Cytochrome P450 3A and P-glycoprotein Dramatically Increases Docetaxel Oral Bioavailability and Risk of Intestinal Toxicity. Cancer Research, 2009, 69, 8996-9002. | 0.9 | 88 |
| 39 | Functionally Overlapping Roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the Elimination of Methotrexate and Its Main Toxic Metabolite 7-Hydroxymethotrexate In vivo. Clinical Cancer Research, 2009, 15, 3084-3093. | 7.0 | 87 |
| 40 | An Experimenterâ€™s Guide to Glioblastoma Invasion Pathways. Trends in Molecular Medicine, 2018, 24, 763-780. | 6.7 | 86 |
| 41 | The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice. Cancer Chemotherapy and Pharmacology, 2004, 53, 173-178. | 2.3 | 85 |
| 42 | Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2. Neoplasia, 2018, 20, 710-720. | 5.3 | 84 |
| 43 | Phase I and Pharmacokinetic Study of Oral Paclitaxel. Journal of Clinical Oncology, 2000, 18, 2468-2475. | 1.6 | 83 |
| 44 | P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 Determine the Pharmacokinetics of Etoposide. Clinical Cancer Research, 2010, 16, 130-140. | 7.0 | 79 |
| 45 | Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Metâ€“driven Pancreatic Carcinoma. Cancer Research, 2013, 73, 6745-6756. | 0.9 | 79 |
| 46 | Sensitivity and Acquired Resistance of BRCA1;p53-Deficient Mouse Mammary Tumors to the Topoisomerase I Inhibitor Topotecan. Cancer Research, 2010, 70, 1700-1710. | 0.9 | 76 |
| 47 | Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo. Molecular Cancer Therapeutics, 2009, 8, 3350-3359. | 4.1 | 74 |
| 48 | The importance of drug-transporting P-glycoproteins in toxicology. Toxicology Letters, 2001, 120, 31-41. | 0.8 | 72 |
| 49 | Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice. Investigational New Drugs, 2004, 22, 219-229. | 2.6 | 71 |
| 50 | Prolonged Ezh2 Depletion in Glioblastoma Causes a Robust Switch in Cell Fate Resulting in Tumor Progression. Cell Reports, 2015, 10, 383-397. | 6.4 | 70 |
| 51 | The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients. British Journal of Cancer, 2001, 85, 1472-1477. | 6.4 | 68 |
| 52 | P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib. Investigational New Drugs, 2015, 33, 1012-1019. | 2.6 | 68 |
| 53 | Glycosylated extracellular vesicles released by glioblastoma cells are decorated by CCL18 allowing for cellular uptake via chemokine receptor CCR8. Journal of Extracellular Vesicles, 2018, 7, 1446660. | 12.2 | 64 |
| 54 | Determination of paclitaxel and metabolites in mouse plasma, tissues, urine and faeces by semi-automated reversed-phase high-performance liquid chromatography. Biomedical Applications, 1995, 664, 383-391. | 1.7 | 63 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Determination of doxorubicin and metabolites in murine specimens by high-performance liquid chromatography. Biomedical Applications, 1998, 712, 129-143. | 1.7 | 62 |
| 56 | Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours. Nature Communications, 2020, 11, 3157. | 12.8 | 59 |
| 57 | Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut. Cancer Chemotherapy and Pharmacology, 2002, 49, 119-125. | 2.3 | 57 |
| 58 | <scp>ABCB</scp>1 and <scp>ABCG</scp>2 restrict the brain penetration of a panel of novel <scp>EZH</scp>2â€inhibitors. International Journal of Cancer, 2015, 137, 2007-2018. | 5.1 | 57 |
| 59 | Characterisation of tumour vasculature in mouse brain by USPIO contrast-enhanced MRI. British Journal of Cancer, 2008, 98, 1784-1789. | 6.4 | 56 |
| 60 | Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the In vivo Elimination of Methotrexate and its Main Toxic Metabolite 7-hydroxymethotrexate. Clinical Cancer Research, 2008, 14, 8152-8160. | 7.0 | 56 |
| 61 | High-grade glioma mouse models and their applicability for preclinical testing. Cancer Treatment Reviews, 2009, 35, 714-723. | 7.7 | 56 |
| 62 | PI3Kâ€“mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models. Clinical Cancer Research, 2017, 23, 1286-1298. | 7.0 | 56 |
| 63 | Therapy-resistant tumor microvascular endothelial cells contribute to treatment failure in glioblastoma multiforme. Oncogene, 2013, 32, 1539-1548. | 5.9 | 55 |
| 64 | Identification of a Druggable Pathway Controlling Glioblastoma Invasiveness. Cell Reports, 2017, 20, 48-60. | 6.4 | 55 |
| 65 | The impact of Pâ€glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors. International Journal of Cancer, 2018, 142, 381-391. | 5.1 | 55 |
| 66 | Tumor microvasculature supports proliferation and expansion of gliomaâ€propagating cells. International Journal of Cancer, 2009, 125, 1222-1230. | 5.1 | 53 |
| 67 | Cognitive impact of cytotoxic agents in mice. Psychopharmacology, 2015, 232, 17-37. | 3.1 | 53 |
| 68 | Isolation, purification, and biological activity of mono- and dihydroxylated paclitaxel metabolites from human feces. Cancer Chemotherapy and Pharmacology, 1995, 36, 299-304. | 2.3 | 52 |
| 69 | Rapid and Robust Transgenic High-Grade Glioma Mouse Models for Therapy Intervention Studies. Clinical Cancer Research, 2010, 16, 3431-3441. | 7.0 | 52 |
| 70 | Buparlisib is a brain penetrable pan-PI3K inhibitor. Scientific Reports, 2018, 8, 10784. | 3.3 | 52 |
| 71 | Magnetic resonance imagingâ€based detection of glial brain tumors in mice after antiangiogenic treatment. International Journal of Cancer, 2008, 122, 1981-1986. | 5.1 | 51 |
| 72 | High Impact of Oatp1a/1b Transporters on In Vivo Disposition of the Hydrophobic Anticancer Drug Paclitaxel. Clinical Cancer Research, 2011, 17, 294-301. | 7.0 | 49 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Intratumoural administration of cisplatin in slow-release devices: II. pharmacokinetics and intratumoural distribution. Cancer Chemotherapy and Pharmacology, 1991, 27, 347-353. | 2.3 | 48 |
| 74 | Impact of Abcc2 [Multidrug Resistance-Associated Protein (Mrp) 2], Abcc3 (Mrp3), and Abcg2 (Breast) Tj ETQq0 0 0 rgBT /Overlock 10 T<br>7-Hydroxymethotrexate. Drug Metabolism and Disposition, 2011, 39, 1338-1344. | 3.3 | 48 |
| 75 | Abcc4 Together with Abcb1 and Abcg2 Form a Robust Cooperative Drug Efflux System That Restricts the Brain Entry of Camptothecin Analogues. Clinical Cancer Research, 2013, 19, 2084-2095. | 7.0 | 48 |
| 76 | Tryptophan depletion results in tryptophan-to-phenylalanine substitutants. Nature, 2022, 603, 721-727. | 27.8 | 47 |
| 77 | Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma. Clinical Cancer Research, 2020, 26, 3319-3332. | 7.0 | 44 |
| 78 | The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery. Investigational New Drugs, 2000, 18, 231-241. | 2.6 | 43 |
| 79 | Determination of imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography. Biomedical Chromatography, 2007, 21, 747-754. | 1.7 | 43 |
| 80 | In vivo disposition of doxorubicin is affected by mouse Oatp1a/1b and human OATP1A/1B transporters. International Journal of Cancer, 2014, 135, 1700-1710. | 5.1 | 43 |
| 81 | <scp>SLC</scp> 1A3 contributes to Lâ€asparaginase resistance in solid tumors. EMBO Journal, 2019, 38, e102147. | 7.8 | 41 |
| 82 | A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A. Cancer Chemotherapy and Pharmacology, 2001, 47, 347-354. | 2.3 | 39 |
| 83 | P-glycoprotein and Mrp1 collectively protect the bone marrow from vincristine-induced toxicity in vivo. British Journal of Cancer, 2003, 89, 1776-1782. | 6.4 | 39 |
| 84 | Cannulation of the jugular vein in mice: a method for serial withdrawal of blood samples. Laboratory Animals, 2003, 37, 181-187. | 1.0 | 37 |
| 85 | Neurobiological changes by cytotoxic agents in mice. Behavioural Brain Research, 2016, 299, 19-26. | 2.2 | 36 |
| 86 | The G2 checkpointâ€”a nodeâ€based molecular switch. FEBS Open Bio, 2017, 7, 439-455. | 2.3 | 36 |
| 87 | Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study. British Journal of Cancer, 2001, 84, 604-610. | 6.4 | 35 |
| 88 | Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography. Biomedical Applications, 1996, 681, 355-362. | 1.7 | 34 |
| 89 | OATP1A/1B Transporters Affect Irinotecan and SN-38 Pharmacokinetics and Carboxylesterase Expression in Knockout and Humanized Transgenic Mice. Molecular Cancer Therapeutics, 2014, 13, 492-503. | 4.1 | 33 |
| 90 | EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy. Clinical Cancer Research, 2019, 25, 4351-4362. | 7.0 | 33 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drugâ€“Drug Interactions in Vivo. Molecular Pharmaceutics, 2015, 12, 4259-4269. | 4.6 | 32 |
| 92 | ATP-binding cassette transporters restrict drug delivery and efficacy against brain tumors even when blood-brain barrier integrity is lost. Cell Reports Medicine, 2021, 2, 100184. | 6.5 | 32 |
| 93 | A simple and sensitive assay for the quantitative analysis of paclitaxel in human and mouse plasma and brain tumor tissue using coupled liquid chromatography and tandem mass spectrometry. Journal of Mass Spectrometry, 2004, 39, 1506-1512. | 1.6 | 31 |
| 94 | MELK Inhibition in Diffuse Intrinsic Pontine Glioma. Clinical Cancer Research, 2018, 24, 5645-5657. | 7.0 | 30 |
| 95 | The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel. Anti-Cancer Drugs, 2001, 12, 351-358. | 1.4 | 29 |
| 96 | Extensive Metabolism and Hepatic Accumulation of Gemcitabine After Multiple Oral and Intravenous Administration in Mice. Drug Metabolism and Disposition, 2008, 36, 1606-1615. | 3.3 | 29 |
| 97 | Mps1 inhibitors synergise with low doses of taxanes in promoting tumour cell death by enhancement of errors in cell division. British Journal of Cancer, 2018, 118, 1586-1595. | 6.4 | 29 |
| 98 | Differential effects of anticoagulants on tumor development of mouse cancer cell lines B16, K1735 and CT26 in lung. Clinical and Experimental Metastasis, 2009, 26, 171-178. | 3.3 | 28 |
| 99 | In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2. Molecular Cancer Therapeutics, 2007, 6, 3307-3313. | 4.1 | 27 |
| 100 | Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration. Anti-Cancer Drugs, 2000, 11, 813-820. | 1.4 | 26 |
| 101 | Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the Bloodâ€“Brain Barrier without restriction by ABCB1 and ABCG2. International Journal of Cancer, 2013, 133, 1222-1233. | 5.1 | 26 |
| 102 | EZN-2208 (PEG-SN38) Overcomes ABCG2-Mediated Topotecan Resistance in BRCA1-Deficient Mouse Mammary Tumors. PLoS ONE, 2012, 7, e45248. | 2.5 | 24 |
| 103 | Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA. Investigational New Drugs, 2013, 31, 1125-1135. | 2.6 | 24 |
| 104 | Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry. Analytical and Bioanalytical Chemistry, 2005, 382, 1484-1490. | 3.7 | 23 |
| 105 | Analytical methods for the determination of vinca alkaloids in biological specimens: A survey of the literature. Journal of Pharmaceutical and Biomedical Analysis, 1991, 9, 1077-1082. | 2.8 | 22 |
| 106 | Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinorelbine in mice as determined by high performance liquid chromatography. Investigational New Drugs, 1993, 11, 141-150. | 2.6 | 21 |
| 107 | Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux. CNS Oncology, 2013, 2, 271-288. | 3.0 | 21 |
| 108 | MEK/MELK inhibition and bloodâ€“brain barrier deficiencies in atypical teratoid/rhabdoid tumors. Neuro-Oncology, 2020, 22, 58-69. | 1.2 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Determination of topotecan in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography. Biomedical Chromatography, 2007, 21, 1191-1200. | 1.7 | 20 |
| 110 | Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice. Investigational New Drugs, 2011, 29, 768-776. | 2.6 | 20 |
| 111 | ABCB1 Attenuates the Brain Penetration of the PARP Inhibitor AZD2461. Molecular Pharmaceutics, 2018, 15, 5236-5243. | 4.6 | 20 |
| 112 | Tissue disposition, excretion and metabolism of vinblastine in mice as determined by high-performance liquid chromatography. Cancer Chemotherapy and Pharmacology, 1993, 32, 286-292. | 2.3 | 19 |
| 113 | Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo. European Journal of Cancer, 2013, 49, 2059-2064. | 2.8 | 19 |
| 114 | Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Bloodâ€“Brain Barrier Using Elacridar and <sup>11</sup>C-Erlotinib PET. Journal of Nuclear Medicine, 2018, 59, 973-979. | 5.0 | 19 |
| 115 | Monitoring Carboplatin Concentrations in Saliva. Therapeutic Drug Monitoring, 1995, 17, 465-470. | 2.0 | 18 |
| 116 | Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion. Anti-Cancer Drugs, 1999, 10, 17-24. | 1.4 | 18 |
| 117 | Trabectedin (ET-743, Yondelisâ„¢) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype. Investigational New Drugs, 2007, 25, 1-7. | 2.6 | 18 |
| 118 | Expression and Cellular Distribution of P-Glycoprotein and Breast Cancer Resistance Protein in Amyotrophic Lateral Sclerosis Patients. Journal of Neuropathology and Experimental Neurology, 2020, 79, 266-276. | 1.7 | 17 |
| 119 | Validated method for the determination of the novel organo-ruthenium anticancer drug NAMI-A in human biological fluids by Zeeman atomic absorption spectrometry. Fresenius' Journal of Analytical Chemistry, 2001, 369, 442-445. | 1.5 | 15 |
| 120 | A serum and platelet-rich plasma serotonin assay using liquid chromatography tandem mass spectrometry for monitoring of neuroendocrine tumor patients. Clinica Chimica Acta, 2017, 469, 130-135. | 1.1 | 15 |
| 121 | Metabolism of paclitaxel in mice. Anti-Cancer Drugs, 2003, 14, 203-209. | 1.4 | 14 |
| 122 | Metabolism of docetaxel in mice. Cancer Chemotherapy and Pharmacology, 2005, 56, 299-306. | 2.3 | 14 |
| 123 | Strategies to target drugs to gliomas and CNS metastases of solid tumors. Journal of Neurology, 2016, 263, 428-440. | 3.6 | 14 |
| 124 | Development and validation of a method to determine the unbound paclitaxel fraction in human plasma. Analytical Biochemistry, 2004, 324, 11-15. | 2.4 | 12 |
| 125 | Evaluation of Human Plasma Protein Binding of Trabectedin (Yondelis™, ET-743). Current Clinical Pharmacology, 2009, 4, 38-42. | 0.6 | 12 |
| 126 | Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice. Investigational New Drugs, 2010, 28, 145-155. | 2.6 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Phase I study of Carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule. British Journal of Cancer, 1999, 79, 1454-1461. | 6.4 | 11 |
| 128 | â€œEffect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183â€• Investigational New Drugs, 2014, 32, 1083-1095. | 2.6 | 11 |
| 129 | Plasma membrane targeting by short chain sphingolipids inserted in liposomes improves anti-tumor activity of mitoxantrone in an orthotopic breast carcinoma xenograft model. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 94, 207-219. | 4.3 | 11 |
| 130 | The vascular compartment hampers accurate determination of teniposide penetration into brain tumor tissue. Cancer Chemotherapy and Pharmacology, 1997, 40, 330-334. | 2.3 | 10 |
| 131 | A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling. Cancer Chemotherapy and Pharmacology, 2002, 50, 16-24. | 2.3 | 10 |
| 132 | The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice. Cancer Chemotherapy and Pharmacology, 2006, 57, 819-825. | 2.3 | 10 |
| 133 | Abstract 5687: Development of glutathione pegylated liposomal doxorubicin (2B3-101) for the treatment of brain cancer. , 2012, , . | | 10 |
| 134 | Cremophor EL pharmacokinetics in a phase I study of paclitaxel (TaxolÂ®) and carboplatin in non-small cell lung cancer patients. Anti-Cancer Drugs, 2000, 11, 687-694. | 1.4 | 9 |
| 135 | Determination of cyclosporin A in human and mouse plasma by reversed-phase high-performance liquid chromatography. Biomedical Applications, 2001, 763, 201-206. | 1.7 | 9 |
| 136 | Clinical pharmacokinetics of an amorphous solid dispersion tablet of elacridar. Drug Delivery and Translational Research, 2017, 7, 125-131. | 5.8 | 9 |
| 137 | ATP-binding cassette transporters limit the brain penetration of Wee1 inhibitors. Investigational New Drugs, 2018, 36, 380-387. | 2.6 | 8 |
| 138 | Retrospective analysis of serum testosterone levels by LC-MS/MS in chemically castrated prostate cancer patients: Biological variation and analytical performance specifications. Clinica Chimica Acta, 2021, 521, 70-75. | 1.1 | 8 |
| 139 | Phase I and pharmacologic study of weekly doxorubicin and 1 h infusional paclitaxel in patients with advanced breast cancer. Anti-Cancer Drugs, 1998, 9, 665-763. | 1.4 | 7 |
| 140 | Simultaneous determination of AZD1152 (prodrug) and AZD1152-hydroxyquinazoline pyrazol anilide by reversed phase liquid chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 3549-3555. | 2.3 | 7 |
| 141 | Serum Testosterone by Liquid Chromatography Tandem Mass Spectrometry for Routine Clinical Diagnostics. Methods in Molecular Biology, 2018, 1730, 93-102. | 0.9 | 7 |
| 142 | Determination of NVP-BEZ235, a dual PI3K and mTOR inhibitor, in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography with fluorescence detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 901, 9-17. | 2.3 | 6 |
| 143 | Sensitive method for plasma and tumor Ko143 quantification using reversed-phase high-performance liquid chromatography and fluorescence detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2013, 913-914, 129-136. | 2.3 | 6 |
| 144 | ABCB1 and ABCG2 Restrict Brain and Testis Accumulation and, Alongside CYP3A, Limit Oral Availability of the Novel TRK Inhibitor Selitrectinib. Molecular Cancer Therapeutics, 2021, 20, 1173-1182. | 4.1 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | High-performance liquid chromatographic bio-analysis of PSC 833 in human and murine plasma. Biomedical Applications, 1998, 719, 251-257. | 1.7 | 5 |
| 146 | Fully automated high-performance liquid chromatographic method for the determination of carzelesin (U-80,244) and metabolites (U-76,073 and U-76,074) in human plasma. Biomedical Applications, 1994, 652, 51-58. | 1.7 | 4 |
| 147 | High-performance liquid chromatography analysis of a novel small-molecule, anti-cancer drug, Palomid 529, in human and mouse plasma and in mouse tissue homogenates. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 3823-3831. | 2.3 | 4 |
| 148 | From Mouse to Man: Predictions of Human Pharmacokinetics of Orally Administered Docetaxel From Preclinical Studies. Journal of Clinical Pharmacology, 2012, 52, 370-380. | 2.0 | 4 |
| 149 | BCRP expression in schwannoma, plexiform neurofibroma and MPNST. Oncotarget, 2017, 8, 88751-88759. | 1.8 | 4 |
| 150 | Abstract 5537: GSH-conjugation improves efficacy of Doxil against intracranial xenografts. , 2010, , . | | 3 |
| 151 | Protocol for live-cell imaging during Tumor Treating Fields treatment with Inovitro Live. STAR Protocols, 2022, 3, 101246. | 1.2 | 3 |
| 152 | Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinleucinol in mice as determined by high-performance liquid chromatography. Cancer Chemotherapy and Pharmacology, 1994, 33, 425-434. | 2.3 | 2 |
| 153 | A population pharmacokinetic model for Cremophor EL using nonlinear mixed-effect modeling: model building and validation. British Journal of Clinical Pharmacology, 2002, 53, 552P-553P. | 2.4 | 1 |
| 154 | Abstract LB-49: ABC transporters in the blood-brain barrier limit the brain penetration of the PARP inhibitor ABT-888. , 2010, , . | | 1 |
| 155 | Abstract A148: Palomid 529, a dual mTor1/2 inhibitor, efficiently penetrates the bloodâ€brain barrier and may be an attractive agent for treatment of glioblastoma. , 2009, , . | | 1 |
| 156 | Tooth Formation as Experimental Model to Study Chemotherapy on Tissue Development: Effect of a Specific Dose of Temozolomide/Veliparib. Genes, 2022, 13, 1198. | 2.4 | 1 |
| 157 | Experimental models to evaluate the role of P-glycoprotein in the bloodâ€“brain tumor barrier. International Congress Series, 2005, 1277, 123-130. | 0.2 | 0 |
| 158 | HG-52MELK INHIBITION AS A POTENTIAL TREATMENT FOR DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2016, 18, iii59.1-iii59. | 1.2 | 0 |
| 159 | DIPG-15. EFFECTIVE PRECLINICAL TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA BY MELK INHIBITION. Neuro-Oncology, 2017, 19, iv7-iv8. | 1.2 | 0 |
| 160 | DIPG-05. PRECLINICAL EFFICACY OF MELK INHIBITION IN DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2018, 20, i49-i50. | 1.2 | 0 |
| 161 | DIPG-04. INHIBITION OF AXL SENSITIZES DIFFUSE INTRINSIC PONTINE GLIOMA TO CYTOTOXIC THERAPIES. Neuro-Oncology, 2018, 20, i49-i49. | 1.2 | 0 |
| 162 | Comments on: â€œSynergistic activity of mTORC1/2 kinase and MEK inhibitors suppresses pediatric low-grade glioma tumorigenicity and vascularityâ€. Neuro-Oncology, 2020, 22, 1404-1405. | 1.2 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Drug Repurposing Screen on Patient-Derived Organoids Identifies New Therapeutic Drug Combination Against KRAS Mutant Colon Cancer. SSRN Electronic Journal, 0, , . | 0.4 | 0 |
| 164 | Indisulam Synergizes With Palbociclib to Induce Senescence Through Inhibition of CDK2 Kinase Activity. SSRN Electronic Journal, 0, , . | 0.4 | 0 |
| 165 | Abstract PO-003: Mitotic enrichment as an efficient radiosensitization strategy. , 2021, , . | | 0 |
| 166 | Abstract 4187: A rapid and robust transgenic high-grade glioma mouse model for therapy-intervention studies. , 2010, , . | | 0 |
| 167 | Abstract LB-301: The impact of Abcb1 and Abcg2 on the brain penetration of PI3K-mTOR inhibitors. , 2010, , . | | 0 |
| 168 | Abstract LB-210: Impact of ABC-transporters in the blood-brain barrier on the efficacy of the PARP inhibitor ABT-888 against transplanted and spontaneous murine brain tumors. , 2011, , . | | 0 |
| 169 | Abstract 5718: Implementation of Î¼-Image Guided Radio-Therapy in the treatment of experimental glioma mouse models: Assessment of the potential of agents that interfere with DNA repair. , 2012, , . | | 0 |
| 170 | Abstract 966: Effect of ABC drug transporters (BCRP, MDR1, MRP2) on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA .. , 2013, , . | | 0 |
| 171 | Abstract 3607: Loss-of-function screens using haploid KBM7 and HAP1 cells to identify mechanisms of anti-cancer drug resistance. , 2015, , . | | 0 |
| 172 | Have we considered all barriers to mammalian target of rapamycin inhibition as treatment for diffuse intrinsic pontine glioma?. Translational Cancer Research, 2017, 6, S1431-S1434. | 1.0 | 0 |
| 173 | Abstract 92: Increasing TTFields treatment efficacy by targeting G2 cell cycle checkpoint. , 2020, , . | | 0 |
| 174 | DDRE-32. ABC TRANSPORTERS RESTRICT THE BRAIN PENETRATION AND INTRACRANIAL EFFICACY OF ANTICANCER AGENTS EVEN WHEN BLOOD-BRAIN BARRIER INTEGRITY IS LOST. Neuro-Oncology, 2020, 22, ii68-ii68. | 1.2 | 0 |
| 175 | EXTH-72. CONTINUOUS INFUSION STUDIES REVEAL THE POTENCY OF ELACRIDAR TO ACT AS A PHARMACO-ENHANCER FOR TREATMENT OF INTRACRANIAL DISEASES BY INHIBITING ABCB1 AND ABCG2 AT THE BLOOD-BRAIN BARRIER. Neuro-Oncology, 2020, 22, ii103-ii103. | 1.2 | 0 |
| 176 | DDRE-01. ACQUIRED AND INTRINSIC RESISTANCE TO VEMURAFENIB IN BRAFV600E-DRIVEN MELANOMA BRAIN METASTASES. Neuro-Oncology, 2020, 22, ii61-ii61. | 1.2 | 0 |
| 177 | EXTH-31. INCREASING TUMOR TREATING FIELDS (TTFIELDS) EFFICACY BY TARGETING THE G2 CELL CYCLE CHECKPOINT WITH WEE1 OR CHK1 INHIBITORS IN GLIOBLASTOMA CELL LINES. Neuro-Oncology, 2020, 22, ii93-ii93. | 1.2 | 0 |
| 178 | RBIO-05. MITOTIC ENRICHMENT AS AN EFFICIENT STRATEGY TO RADIOSENSITIZE GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii193-ii193. | 1.2 | 0 |
| 179 | Abstract LB-255: Acquired and intrinsic resistance to vemurafenib in BRAF<sup>v600e</sup>-driven melanoma brain metastases. , 2019, , . | | 0 |
| 180 | Abstract 4419: Cell cycle analysis during TTF to exploit novel targets for increasing treatment efficacy. , 2019, , . | | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinleucinol in mice as determined by high-performance liquid chromatography. Cancer Chemotherapy and Pharmacology, 1994, 33, 425-434. | 2.3 | 0 |